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Background: Mutations of fibroblast growth factor receptor 2 (FGFR2) account for a higher proportion of genetic
cases of craniosynostosis than any other gene, and are associated with a wide spectrum of severity of clinical
problems. Many of these mutations are highly recurrent and their associated features well documented. Crouzon
syndrome is typically caused by heterozygous missense mutations in the third immunoglobulin domain of FGFR2.
Case presentation: Here we describe two families, each segregating a different, previously unreported FGFR2
mutation of the same nucleotide, c.1083A>G and c.1083A>T, both of which encode an apparently synonymous
change at the Pro361 codon. We provide experimental evidence that these mutations affect normal FGFR2 splicing
and document the clinical consequences, which include a mild Crouzon syndrome phenotype and reduced
penetrance of craniosynostosis.
Conclusions: These observations add to a growing list of FGFR2 mutations that affect splicing and provide
important clinical information for genetic counselling of families affected by these specific mutations.
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Craniosynostosis defines the premature fusion of the
cranial sutures and has an overall prevalence of 1 in
2100–2300 live births [1,2]. Nearly one quarter of
craniosynostosis has a genetic aetiology [3,4]; there is
considerable genetic heterogeneity and frequent phenotypic
overlap between different syndromes. Genes encoding three
members of the fibroblast growth factor receptor family
(FGFR1, FGFR2 and FGFR3) are commonly mutated in in-
dividuals with craniosynostosis. Heterozygous mutations in
FGFR2, which are frequently recurrent, account for ~28%
of genetic cases [4] and cause Crouzon [5,6], Pfeiffer [7-9],
Apert [10], Beare-Stevenson [11] and bent bone dysplasia
[12] syndromes. All involve synostosis of the coronal
and other cranial sutures, a distinctive “crouzonoid”
craniofacial appearance (comprising hypertelorism,* Correspondence: andrew.wilkie@imm.ox.ac.uk
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unless otherwise stated.exorbitism, prominent nose, and midface hypoplasia),
but differ in the presence and extent of abnormalities
of the hands and feet, other skeletal manifestations
and dermatological features [13,14].
FGFR2, like the other members of the FGFR family,
comprises an extracellular ligand-binding region (com-
posed of three immunoglobulin-like domains), a single
transmembrane peptide and a cytoplasmic tyrosine kin-
ase domain. Mutually exclusive alternative splicing of exons
IIIb and IIIc gives rise to epithelial and mesenchymal
isoforms (FGFR2b and FGFR2c) respectively [15]. These
alternative extracellular domains interact with different
repertoires of fibroblast growth factors (FGFs) to regulate
downstream processes such as proliferation, differenti-
ation and cell migration [16].
Here we describe two families heterozygous for the
same, previously unreported apparently synonymous vari-
ant in FGFR2 [p.(Pro361Pro)], although caused by differ-
ing nucleotide substitutions. The mutation carriers in
both families exhibit features of mild Crouzon syndrome,
and a minority required craniofacial surgery. We propose
that this variant is in fact pathogenic and demonstrate the
generation of abnormal cDNA products resulting froml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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finding highlights the challenges posed in interpreting
such synonymous variants when providing genetic coun-
selling for affected families.
Case presentations
Family 1
Individual III-1 (Figure 1A) was born after a normal
pregnancy and was referred for craniofacial assessment
at two years of age because prominent eyes and a head
tilt. Her father II-1 (Figure 1B), grandmother I-1 and
two deceased uncles were all said to have a similar appear-
ance with prominent staring eyes, but had not required
any surgery. She had an occipitofrontal circumference
(OFC) of 50 cm (+1.1 SD) and was noted to have a mildly
crouzonoid appearance, with slight exorbitism and mid-
face retrusion. In view of the mild crouzonoid features,
sequencing of FGFR2 exons IIIa and IIIc was requested.
This demonstrated a heterozygous c.1083A>G [p.
(Pro361Pro)] variant within exon IIIc, which was also
present in II-1 and I-1.
Computed tomography (CT) of the skull of individual
III-1 at the age of 2.8 years demonstrated right lambdoid
and occipitomastoid synostosis, all other major cranial
sutures being patent. Ophthalmological review identified
slightly reduced visual acuity and a latent divergent
squint with slight left hypophoria. The patient is now
four years old and has not undergone any surgicalFigure 1 Pedigrees and facial features of individuals with FGFR2mutati
craniosynostosis and hatched symbols represent individuals with a similar cro
heterozygosity for c.1083A>G. B, Facial appearance of II-1 from Family 1 aged
part A.†confirmed heterozygosity for c.1083A>T. D, Facial appearance of III-1 fintervention, as she has a good overall head shape with no
major midface retrusion, is making good developmental
progress, and has no features to suggest significant intra-
cranial restriction.
Family 2
The male proband (III-2 in Figure 1C), born after an
uneventful pregnancy, was referred for craniofacial as-
sessment at the age of three months. Physical examin-
ation showed a mild cloverleaf skull with temporal
bulging and reduced OFC (36 cm; −2.2 SD), hypertelorism,
and severe exorbitism mainly at the infra-orbital level.
Skull X-ray and CT showed pansynostosis and multiple
craniolacunae, with no intracerebral anomalies.
Owing to the severe peri-orbital features and the ab-
sence of deformations of the upper and lower extrem-
ities a clinical diagnosis of Crouzon syndrome was
suggested. The patient’s mother, grandmother and several
cousins were reported to show mild facial features also
suggestive of this diagnosis.
The proband underwent fronto-orbital advancement
at the age of five months. Since the occiput was still se-
verely flattened and both lambdoid sutures were fused, oc-
cipital craniotomy and remodelling was performed at the
age of twelve months. Clumsiness and motor delay were
first noted aged 18 months; psychological testing at the
age of 12.8 years gave scores for non-verbal intelligence of
80 (SON-R) and visual-motor integration of 81. Clonidineons. A, Pedigree of Family 1; solid symbols represent clinically confirmed
uzonoid appearance but without confirmed craniosynostosis. *confirmed
33 years. C, Abbreviated pedigree of Family 2; notation of symbols as in
rom Family 2 aged 8.75 years (left) and 43 years (right).
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went special education. During childhood, the exorbitism
increased requiring further orbital advancement and
cranial vault remodelling at the age of eight years. Several
deciduous and permanent teeth were extracted because of
Class III malocclusion and dental crowding.
Genetic testing of FGFR2 was performed, identifying the
heterozygous point mutation c.1083A>T [p.(Pro361Pro);
Figure 2A]. This variant was also present in his mother II-1.
Independently of these events, a second patient (III-1)
was referred to the same clinic at the age of ten years
with a scaphocephalic head shape. He had previously
undergone vault remodelling at the age of 16 months
owing to bicoronal synostosis. At the time of referral, he
had an occipito-frontal circumference of 48.5 cm (−2.8 SD),
hypertelorism and severe exorbitism. In addition, he hadFigure 2 Genomic context and consequences of FGFR2mutations. A, Sc
c.1083A>T mutations (not to scale). IIIa, IIIb and IIIc denote exons of FGFR2 en
skipping of exon IIIb normally occurs in blood mRNA.TM, exon encoding
heterozygosity for c.1083A>G (II-1, Family 1) or c.1083A>T (III-2, Family 2)
dashed red line; the upper line in each trace shows the wild type sequen
cryptic donor splice site within exon IIIc (marked with red asterisk). B, Amplifie
individuals as for genomic analyses), demonstrates two additional smaller pro
normal (C) product. C, In the cDNA product coincident with the wild type ba
IIIc is not represented, indicating complete skipping of normal splicing. The co
are from III-1, Family 2) are either to activate the cryptic splice donor site withmild maxillary hypoplasia and both 2nd premolars of the
lower jaw were absent. Ophthalmic examination showed
myopia with divergent strabismus of the right eye associ-
ated with reduced visual acuity. A monobloc procedure
without distraction (Le Fort III and an advancement of the
forehead) was performed.
Due to the severe peri-orbital features a diagnosis of
Crouzon syndrome was suggested. Analysis of FGFR2
identified the heterozygous point mutation c.1083A>T [p.
(Pro361Pro)]. His father, grandmother and great-
grandmother had a similar craniofacial appearance. Based
on the pedigree analysis, it is evident that III-1 and III-2
are third cousins and that the FGFR2 mutation present in
these two branches is identical by descent (Figure 1C).
Apart from III-1 and III-2, none of the other affected fam-
ily members had undergone craniofacial surgery.hematic representation of genomic region affected by c.1083A>G and
coding the 3rd immunoglobulin-like domain; note that physiological
transmembrane domain. Sequencing of genomic DNA demonstrates
mutation at the −2 position from the end of exon IIIc (indicated by
ce). Below the cartoon is shown the genomic sequence around the
d cDNA corresponding to c.1083A>G and c.1083A>T mutations (same
ducts (indicated with white arrows D and E), in addition to the
nd (II-1, Family 1), the mutant allele at the penultimate position of exon
nsequences for splicing of the mutant allele (sequence traces illustrated
in exon IIIc (D) or to skip exon IIIc completely (E).
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Ethics approval for the study was obtained from NRES
Committee London - Riverside (09/H0706/20) and the
Medical Ethical Committee of the Erasmus University
Medical Center Rotterdam (MEC-2013-547). Venous blood
was collected into PAXgene Blood RNA tubes (Qiagen)
from individuals II-1 (Family 1) and III-1 (Family 2), and
RNA was extracted according to the associated protocol.
cDNA was synthesized using the Fermentas RevertAid
First-Strand Synthesis kit with random hexamer primers
according to the manufacturer’s instructions.
cDNA was amplified using a forward primer in FGFR2
exon IIIa (5′-TCGGAGGAGACGTAGAGTTTGTCTG
C-3′) used in combination with a reverse primer in exon
11 (encoding the transmembrane (TM) domain; 5′-TGT
TACCTGTCTCCGCAGGGGGATA-3′). DNA bands were
cut out and gel purified using the Q-Spin gel extraction kit
(Geneflow). Dideoxy sequencing was carried out on the
resulting DNA products. The resulting cDNA products
were numbered according to NCBI Reference Sequence:
NM_000141.4.
Results
The synonymous variants c.1083A>G and c.1083A>T
occur at the −2 position of the 5′ (donor) splice site of
FGFR2 exon IIIc (Figure 2A). The neural network splice
site predictor (http://www.fruitfly.org/seq_tools/splice.html)
generates a score for the wild type donor of 0.88, which is
reduced to 0.37 by the A>G transition, and to 0.19 by the
A>T transversion. In these circumstances, use of a cryptic
splice site (score 0.84) within exon IIIc, 51 nucleotides up-
stream from the end of the exon, is expected based on ana-
lysis of a previous mutation c.1084+3A>G [17]. This would
lead to an in-frame deletion of 17 amino acids.
Amplification of cDNA from individuals heterozygous
for either the FGFR2 c.1083A>G or the c.1083A>T vari-
ants demonstrated the presence of two additional bands,
not present in the wild type control, at approximately
430 bp and 330 bp (Figure 2B). Sequencing of the normal
479 bp product from these individuals showed completeTable 1 Summary of mutations affecting correct splicing of th
Mutation Protein Proposed effect Exper
c.1032G>A p.(Ala344Ala) Activation of cryptic splice site Yes
c.1083A>G p.(Pro361Pro) Loss of normal donor site with use
of alternative cryptic splice site
Yes
c.1083A>T p.(Pro361Pro) As above Yes
c.1084G>T p.(Ala362Ser) Annotated as missense but likely
to affect splicing
No
c.1084+3A>G - Loss of normal donor site with use
of alternative cryptic splice site
Yes
c.1084+3A>C - Loss of normal donor site with use
of alternative cryptic splice site
Noabsence of the mutant allele (illustrated in Figure 2C for II-1
from Family 1), indicating that both mutations abolish use
of the normal exon IIIc donor splice site. Sequencing of
the ~430 bp product confirmed that the cryptic splice
donor within exon IIIc was preferred in the mutant allele
(Figure 2D), while the ~330 bp product demonstrated
complete skipping of exon IIIc (Figure 2E).
Conclusions
In humans there is a consensus sequence around the 5′
splice donor site: A, C or T, AG / gtaagt (where / indicates
the exon-intron boundary). Mutations of the consensus A
at the penultimate nucleotide of the exon have been asso-
ciated previously with loss of splicing at the donor site
[18,19]. Other mutations near the FGFR2 exon IIIc splice
donor site have also been described (Table 1), all associ-
ated with a mild Crouzon phenotype. It is likely that the
p.(Ala362Ser) substitution [20] in fact exerts its pathogenic
effect via the G>T transversion at the −1 position in the
exon, rather than as a missense substitution, but this was
not tested experimentally.
In the cases reported here, the wild type splice donor
site is abolished by the A>G or A>T mutations at the
−2 position from the intron, leading to the cryptic site
being preferred. The apparently greater amount of mu-
tant cDNA products associated with the A>T mutation
appears to correlate both with the greater predicted dis-
ruption of the splice site and with the more severe
phenotype in clinically affected individuals from Family
2 compared with Family 1. However, since the A>G muta-
tion did not support use of the normal exon IIIc donor
splice site (Figure 2C), other explanations for these differ-
ences are possible, such as differing proportions of cell
types in the blood samples analysed, and/or differences in
genetic background.
Utilisation of the cryptic donor would lead to an in-
frame deletion of the last 17 amino acids of exon IIIc
(p.Gly345_Pro361del), including four residues that form
specific contacts with the ligand FGF2 [25]. However as
craniosynostosis-causing FGFR mutations function in ae FGFR2 exon IIIc donor site
imental demonstration Reference
Reardon et al. 1994 [6]; Li et al. 1995 [21];
Del Gatto & Breathnach 1995 [22]
This study
This study
Everett et al. 1999 [20]
Kan et al. 2004 [17]
Cornejo-Roldan, Roessler & Muenke 1999 [23];
Kress et al. 2000 [24]
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that in these individuals a mutant protein is formed which
is prone to forming covalently-linked dimers [26], leading
to variable features of Crouzon syndrome.
Our case reports document the range of phenotypic
consequences associated with these particular mutations.
Whilst a mild crouzonoid phenotype was generally evident,
only a minority of individuals developed overt craniosynos-
tosis requiring calvarial surgery. Orthodontic problems
may also occur but these were not fully documented in our
study. The causes of the clinical variability are unknown,
although one potential factor may be the extent of intra-
uterine fetal head constraint [27].
In conclusion, mutations near the FGFR2 exon IIIc
splice sites should be carefully evaluated as to whether
they may be pathogenic, even if they are synonymous or
outside the canonical AG/GT splice acceptor/donor se-
quences. In particular, the mutations described here are
associated with variable Crouzon syndrome features and
affected families should be counselled as such.
Consent
Written informed consent was obtained from the patients
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
Patient ascertainment and assessment: JACG, JR, AJMH, SAW, IMJM, AOMW.
Experimental analysis: ALF, HL, AMWO. Supervised experiments: TL, AOMW.
Drafted paper: ALF, JACG, AOMW. All authors approved the paper.
Acknowledgements
We thank all families for their participation, J. Frankland and T. Rostron for
DNA sequencing, and W. Baggley for clinical photography. This work was
funded by the Wellcome Trust (093329 and 102731) and Oxford NIHR
Biomedical Research Centre (A.O.M.W).
Author details
1Weatherall Institute of Molecular Medicine, John Radcliffe Hospital,
University of Oxford, Headington, Oxford OX3 9DS, UK. 2Department of
Plastic and Reconstructive Surgery and Hand Surgery, Erasmus MC, University
Medical Center, Rotterdam, The Netherlands. 3Clinical Genetics Department,
Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. 4Genetics
Laboratories, Oxford University Hospitals NHS Trust, Churchill Hospital,
Oxford, UK. 5Department of Clinical Genetics, Erasmus MC, University Medical
Center, Rotterdam, The Netherlands. 6Craniofacial Unit, Oxford University
Hospitals NHS Trust, John Radcliffe Hospital, Oxford, UK.
Received: 9 June 2014 Accepted: 4 August 2014
Published: 31 August 2014
References
1. Boulet SL, Rasmussen SA, Honein MA: A population-based study of
craniosynostosis in metropolitan Atlanta, 1989–2003. Am J Med
Genet A 2008, 146A:984–991.
2. Lajeunie E, Le Merrer M, Bonaiti-Pellie C, Marchac D, Renier D: Genetic
study of nonsyndromic coronal craniosynostosis. Am J Med Genet 1995,
55:500–504.3. Wilkie AO, Byren JC, Hurst JA, Jayamohan J, Johnson D, Knight SJ, Lester T, Richards
PG, Twigg SR, Wall SA: Prevalence and complications of single-gene and
chromosomal disorders in craniosynostosis. Pediatrics 2010, 126:e391–e400.
4. Sharma VP, Fenwick AL, Brockop MS, McGowan SJ, Goos JA, Hoogeboom
AJ, Brady AF, Jeelani NO, Lynch SA, Mulliken JB, Murray DJ, Phipps JM,
Sweeney E, Tomkins SE, Wilson LC, Bennett S, Cornall RJ, Broxholme J,
Kanapin A, 500 Whole-Genome Sequences (WGS500) Consortium, Johnson
D, Wall SA, van der Spek PJ, Mathijssen IMJ, Maxson RE, Twigg SRF, Wilkie
AOM: Mutations in TCF12, encoding a basic helix-loop-helix partner of
TWIST1, are a frequent cause of coronal craniosynostosis. Nat Genet 2013,
45:304–307.
5. Jabs EW, Li X, Scott AF, Meyers G, Chen W, Eccles M, Mao JI, Charnas LR,
Jackson CE, Jaye M: Jackson-Weiss and Crouzon syndromes are allelic
with mutations in fibroblast growth factor receptor 2. Nat Genet 1994,
8:275–279.
6. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S:
Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon
syndrome. Nat Genet 1994, 8:98–103.
7. Lajeunie E, Ma HW, Bonaventure J, Munnich A, Le Merrer M, Renier D:
FGFR2 mutations in Pfeiffer syndrome. Nat Genet 1995, 9:108.
8. Rutland P, Pulleyn LJ, Reardon W, Baraitser M, Hayward R, Jones B, Malcolm
S, Winter RM, Oldridge M, Slaney SF, Poole MD, Wilkie AOM: Identical
mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome
phenotypes. Nat Genet 1995, 9:173–176.
9. Schell U, Hehr A, Feldman GJ, Robin NH, Zackai EH, de Die-Smulders C,
Viskochil DH, Stewart JM, Wolff G, Ohashi H, Price RA, Cohen MM Jr,
Muenke M: Mutations in FGFR1 and FGFR2 cause familial and sporadic
Pfeiffer syndrome. Hum Mol Genet 1995, 4:323–328.
10. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD,
Hayward RD, David DJ, Pulleyn LJ, Rutland P, Malcolm S, Winter RM,
Reardon W: Apert syndrome results from localized mutations of FGFR2
and is allelic with Crouzon syndrome. Nat Genet 1995, 9:165–172.
11. Przylepa KA, Paznekas W, Zhang M, Golabi M, Bias W, Bamshad MJ, Carey
JC, Hall BD, Stevenson R, Orlow S, Cohen MM Jr: Fibroblast growth factor
receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat
Genet 1996, 13:492–494.
12. Merrill AE, Sarukhanov A, Krejci P, Idoni B, Camacho N, Estrada KD, Lyons
KM, Deixler H, Robinson H, Chitayat D, Curry CJ, Lachman RS, Wilcox WR,
Krakow D: Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder,
has deficient canonical FGF signaling. Am J Hum Genet 2012, 90:550–557.
13. Agochukwu NB, Solomon BD, Muenke M: Impact of genetics on the
diagnosis and clinical management of syndromic craniosynostoses.
Childs Nerv Syst 2012, 28:1447–1463.
14. Johnson D, Wilkie AO: Craniosynostosis. Eur J Hum Genet 2011, 19:369–376.
15. Mohammadi M, Olsen SK, Ibrahimi OA: Structural basis for fibroblast
growth factor receptor activation. Cytokine Growth Factor Rev 2005,
16:107–137.
16. Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast
growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139–149.
17. Kan R, Twigg SR, Berg J, Wang L, Jin F, Wilkie AO: Expression analysis of an
FGFR2 IIIc 5′ splice site mutation (1084+3A->G). J Med Genet 2004, 41:e108.
18. Podkrajsek KT, Milenkovic T, Odink RJ, der Grinten HL C-v, Bratanic N, Hovnik
T, Battelino T: Detection of a complete autoimmune regulator gene deletion
and two additional novel mutations in a cohort of patients with atypical
phenotypic variants of autoimmune polyglandular syndrome type 1.
Eur J Endocrinol 2008, 159:633–639.
19. Twigg SR, Vorgia E, McGowan SJ, Peraki I, Fenwick AL, Sharma VP, Allegra M,
Zaragkoulias A, Sadighi Akha E, Knight SJ, Lord H, Lester T, Izatt L, Lampe
AK, Mohammed SN, Stewart FJ, Verloes A, Wilson LC, Healy C, Sharpe PT,
Hammond P, Hughes J, Taylor S, Johnson D, Wall SA, Mavrothalassitis G,
Wilkie AOM: Reduced dosage of ERF causes complex craniosynostosis in
humans and mice and links ERK1/2 signaling to regulation of
osteogenesis. Nat Genet 2013, 45:308–313.
20. Everett ET, Britto DA, Ward RE, Hartsfield JK Jr: A novel FGFR2 gene
mutation in Crouzon syndrome associated with apparent
nonpenetrance. Cleft Palate Craniofac J 1999, 36:533–541.
21. Li X, Park WJ, Pyeritz RE, Jabs EW: Effect of splicing of a silent FGFR2
mutation in Crouzon syndrome. Nat Genet 1995, 9:232.
22. Del Gatto F, Breathnach R: A Crouzon syndrome synonymous mutation
activates a 5′ splice site within the IIIc exon of the FGFR2 gene. Genomics
1995, 27(3):558–559.
Fenwick et al. BMC Medical Genetics 2014, 15:95 Page 6 of 6
http://www.biomedcentral.com/1471-2350/15/9523. Cornejo-Roldan LR, Roessler E, Muenke M: Analysis of the mutational
spectrum of the FGFR2 gene in Pfeiffer syndrome. Hum Genet 1999,
104:425–431.
24. Kress W, Collman H, Busse M, Halliger-Keller B, Mueller CR: Clustering of FGFR2
gene mutations in patients with Pfeiffer and Crouzon syndromes (FGFR2
associated craniosynostosis). Cytogenet Cell Genet 2000, 91(1–4):134–137.
25. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M: Crystal
structures of two FGF-FGFR complexes reveal the determinants of
ligand-receptor specificity. Cell 2000, 101:413–424.
26. Robertson SC, Meyer AN, Hart KC, Galvin BD, Webster MK, Donoghue DJ:
Activating mutations in the extracellular domain of the fibroblast growth
factor receptor 2 function by disruption of the disulfide bond in the
third immunoglobulin-like domain. Proc Natl Acad Sci U S A 1998,
95:4567–4572.
27. Johnson D, Wall SA, Mann S, Wilkie AO: A novel mutation, Ala315Ser, in
FGFR2: a gene-environment interaction leading to craniosynostosis? Eur
J Hum Genet 2000, 8:571–577.
doi:10.1186/s12881-014-0095-4
Cite this article as: Fenwick et al.: Apparently synonymous substitutions in
FGFR2 affect splicing and result in mild Crouzon syndrome. BMC Medical
Genetics 2014 15:95.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
